Search Results
Dec 11, 2025, 08:09 ET Indivumed und University of Rochester Medical Center intensivieren ihre Zusammenarbeit für die patientenzentrierte Entwicklung neuartiger Krebstherapien
Die Kooperation konzentriert sich zunächst auf fortgeschrittene Stadien solider Krebsarten mit hohem medizinischem Bedarf - wie Darmkrebs (CRC), Bauchspeicheldrüsenkrebs (PDAC), Lungenkrebs und Brustkrebs - mit der Möglichkeit, in Zukunft auch auf andere Krebsarten auszuweiten. Die gewonnenen
More news about: Indivumed GmbH
Dec 11, 2025, 08:00 ET HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
≥4-9 months across colorectal cancer (CRC), ovarian cancer, non-small cell lung cancer (NSCLC), and sarcomaCombination Therapy (HCB101-201; NCT06771622)Well-tolerated across gastric cancer (GC), triple-negative breast cancer (TNBC), CRC, and HNSCCNo new safety signals
More news about: HanchorBio Inc.
Dec 10, 2025, 14:37 ET Indivumed 與羅切斯特大學醫學中心拓展合作，以患者為中心探索新型癌症療法
合作成功，我們對其組織及多組學數據方法的熟悉，將為合作奠定良好基礎。新項目將創造更多機會去識別新療法和生物標記，揭示針對臨床決策的『靶點-患者』精準配對，從而協助提升癌症護理水平。」聚焦特定癌症實體的晚期階段合作初期將集中於醫療需求迫切的晚期實體腫瘤，如結直腸癌 (CRC)、胰臟癌 (PDAC)、肺癌及乳癌，未來有望擴展至其他癌症類型。透過此合作夥伴關係獲得的見解，將推動 Indivumed 目前的研究計劃及資產開發，同時為參與的臨床醫生提供寶貴指導，以輔助治療決策。「我們很高興能深化與 URMC 的合作，這將顯著增強我們透過真正以患者為中心的方法，探索新型癌症療法的能力。」Indivumed
More news about: Indivumed GmbH
Dec 10, 2025, 14:10 ET A Indivumed e o Centro Médico da Universidade de Rochester ampliam a colaboração para a descoberta de novas terapias centradas no paciente
específicasA colaboração inicialmente se concentra em estágios avançados de cânceres sólidos com alta necessidade médica, como câncer colorretal (CRC), pancreático (PDAC), de pulmão e de mama, com potencial de se expandir para outros tipos de câncer no futuro. Os insights obtidos por meio dessa parceria
More news about: Indivumed GmbH
Dec 10, 2025, 08:00 ET Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics
of specific entitiesThe collaboration initially focuses on advanced stages of solid cancers with a high medical need, such as colorectal (CRC), pancreatic (PDAC), lung, and breast cancer, with the potential to expand to other cancer types in the future. Insights gained through this partnership
More news about: Indivumed GmbH
Dec 10, 2025, 08:00 ET Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics
of specific entitiesThe collaboration initially focuses on advanced stages of solid cancers with a high medical need, such as colorectal (CRC), pancreatic (PDAC), lung, and breast cancer, with the potential to expand to other cancer types in the future. Insights gained through this partnership
More news about: Indivumed GmbH
Dec 09, 2025, 05:30 ET ICFAI Business School Hyderabad Celebrates 25 Years of Global Case Writing Excellence
Research Center (CRC) at ICFAI Business School (IBS) Hyderabad is proudly celebrating 25 Years of Global Case Writing Excellence, marking a major milestone in its history as a world-leading hub for management case development. The CRC has consistently
More news about: ICFAI Business School (IBS)
Dec 08, 2025, 12:00 ET Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
observed, particularly in patients without prior VEN or menin inhibitor exposure (N=13). The ORR is 85% (11/13) and the composite complete remission (CRc) rate is 62% (8/13). Local MRD assessments were available in 9 patients and 7/9 (78%) achieved MRD negativity as of the cut-off.These data support
More news about: Sumitomo Pharma America
Dec 08, 2025, 08:53 ET CISOs Connect Announces 2026 C100 Winners
JudgesAngela Williams, SVP & Global CISO, UL SolutionsBrett Conlon, CISO, American Century InvestmentsHoward Whyte, CISO, CRC GroupHussein Syed, SVP & CISO, RWJBarnabas HealthJames Blair, CISO, ToddMandy Andress, CISO, ElasticMark Eggleston,
More news about: CISOs Connect
Dec 05, 2025, 08:30 ET Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform
blood-based cancer screening," said Aaron Elliott, Ph.D., CEO of Freenome. "Our technology has been clinically validated through our pivotal PREEMPT CRC study and recent JAMA manuscript. We have secured the commercialization partnerships needed to support the expected launch of multiple tests in 2026.
More news about: Freenome Holdings, Inc.
Dec 02, 2025, 11:00 ET Legal 1031 Exchange Services Welcomes Brittany A. Schuette as Counsel
developers, operators, opportunity funds, commercial lenders, family offices, realtors and regional and national residential lenders. The company is part of CRC Group, one of North America's largest independent wholesale specialty insurance distributors, delivering the broadest range of insurance solutions available
More news about: Kensington Vanguard National Land Services
Dec 01, 2025, 17:31 ET Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
Total Incident Cases of CRCGender-specific Cases of CRCAge-specific Cases of CRCTumor Localization-specific Cases of CRCStage-specific Cases of CRCMutation-specific Cases of CRCTotal Treated Cases of CRC
More news about: DelveInsight Business Research, LLP
Dec 01, 2025, 08:30 ET Galmed Issues CEO Letter to Shareholders
Cancers) drug resistance.These results support our plans to advance Aramchol into a Phase 1/2 clinical trial for metastatic colorectal cancer (CRC), hepatocellular carcinoma (HCC), and cholangiocarcinoma in collaboration with VCU Massey Comprehensive Cancer Center in early 2026.Based
More news about: Galmed Pharmaceuticals Ltd.
Nov 27, 2025, 00:00 ET GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology
58.3%The results remained consistent regardless of: CRC locations (left vs. right colon), age of CRC patients(<60 vs. ≥60), and AA locationsThese findings highlight the test's potential as a reliable cfDNA-based blood test for CRC screening and early prevention.A GC Genome spokes
More news about: GC Genome
Nov 26, 2025, 19:17 ET FGR sichert sich die exklusiven weltweiten Produktions- und Vertriebsrechte für Graphen-Kohlenstoffpaste
die Zusammenarbeit im Rahmen des Cooperative Research Centre Project (CRC-P), die im Juni 2022 bzw. August 2023 geschlossen wurden.Marktreifes Produkt mit zahlreichen AnwendungsbereichenIm Rahmen der bestehenden CRC-P-Partnerschaftsvereinbarung haben FGR und Halocell erfolgreich die
More news about: First Graphene Ltd
Nov 25, 2025, 23:16 ET FGR secures exclusive global graphene carbon paste production and sale rights
Development Agreement and Cooperative Research Centre Project (CRC-P) Partners Agreement reached in June 2022 and August 2023 respectively.Market-ready product with multiple sector applicationsUnder the pre-existing CRC-P Partners Agreement, FGR and Halocell have successfully investigated
More news about: First Graphene Ltd
Nov 25, 2025, 22:56 ET FGR secures exclusive global graphene carbon paste production and sale rights
Development Agreement and Cooperative Research Centre Project (CRC-P) Partners Agreement reached in June 2022 and August 2023 respectively. Market-ready product with multiple sector applications Under the pre-existing CRC-P Partners Agreement, FGR and Halocell have successfully investigated
More news about: First Graphene Ltd
Nov 24, 2025, 14:30 ET IBSAT 2025: Last Call for Applications!
selected 27 B-Schools in India and part of the global 6% that have achieved this recognition. Its in-house Case Research Center (CRC) wins prestigious case awards every year. The CRC was ranked the second-best case research center globally, after Harvard, by the Case Impact Index 2024. IBSAT
More news about: ICFAI Business School (IBS)
Nov 18, 2025, 07:16 ET Zywave Announces 2026 Lineup of Insurance Industry Events
Casualty Insights Conference – NYC – March 5, 2026 Keynote by Dave Obenauer, CEO, CRC GroupZywave's Casualty Insights Conference is the premier insurance industry event addressing today's casualty risk management and insurance
More news about: Zywave
Nov 17, 2025, 11:04 ET Discovery Behavioral Health Appoints Dr. Thomas Britton as CEO
leadership experience, having served as CEO of Accanto Health, American Addiction Centers, Gateway Foundation and prior to that as a division president at CRC. "I am both honored and excited for the opportunity to join DBH in its continued journey towards excellence," Dr. Britton said.
More news about: Discovery Behavioral Health
Nov 17, 2025, 08:30 ET Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
The combination of Aramchol and Stivarga® is expected to enter phase 1b clinical trials early 2026 in metastatic colorectal cancer (CRC), hepatocellular (HCC) and cholangiocarcinoma patients with a planned expansion cohort including metformin.
More news about: Galmed Pharmaceuticals Ltd.
Nov 14, 2025, 11:41 ET AI Takes Center Stage: illumend to Preview Lumie, Its Conversational AI Guide, and New Procore Integration at IRMI Construction Risk Conference
the IRMI Construction Risk Conference (CRC),
More news about: illumend
Nov 12, 2025, 17:31 ET WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight
in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CRC companies, including Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab,
More news about: DelveInsight Business Research, LLP
Nov 12, 2025, 09:30 ET ALKEME Insurance Hosts CarrierVerse 2025 with Record Attendance and Sponsor Support
Platinum Sponsors: Amwins, First Insurance Funding Gold Sponsors: BBSI, CRC Group, UCPM, UKG Silver Sponsors: Capital Premium Financing, RT Specialty, Travelers,
More news about: ALKEME Insurance
Nov 12, 2025, 08:00 ET Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
advanced colorectal cancer (CRC) at the European Society for Medical Oncology (ESMO) Congress. In addition, we will be engaging with regulatory authorities to seek a registrational pathway for sirexatamab and optimizing the DKK1 biomarker assay that could be used to identify CRC patients at risk of poor
More news about: Cypherpunk Technologies Inc.